Med ett händelserikt år 2022 i ryggen där fokus framför allt har varit på att bearbeta den globala m...
Today marks the last day when Zwipe is trading to receive subscription rights.
SyntheticMR växte med 17 procent under 2022 men minskade resultatet.
Following a period of increased clinical activity, Q422, as we noted previously, saw Cantargia narro...
Redeye updates its estimates on Imint following a weak Q4 2022 report, where it broke nine consecuti...
Redeye is positively surprised by the favorable opinion for Tesofensine as an obesity treatment in M...
Nettoomsättningen inkom 9 % högre än våra estimat och kvartalets intäktsökning hänförligt till de tr...
Redeye provides an update on Northbaze's Q4 2022 report.
First Venture publicerade den 23 februari 2023 bolagets delårsrapport för fjärde kvartalet år 2022.
After a comprehensive adjustment of business focus, balance sheet, costs and valuation in 2022, alon...
Redeye updates its view on Beyond Frames after the Q4’22 report.
Calliditas recorded Q4 Tarpeyo sales of SEK 169m which is impressive even if it is just below our an...
Redeye retains its positive view of Infracom following its Q4 2022 report.
Redeye updates its estimates on the back of I-Tech’s Q4’22 report, delivering a significant estimate...
Redeye updates its view post Fragbite Groups Q4 2022 report, where net sales and profitability were ...
Redeye updates its estimates and fair value range following the Q4 report, which showed higher profi...
In conjunction with its Q4 report, BankNordik announced a total dividend of DKK 250m to be paid out ...
Q4'22: Pre-tax profit in line with expectations Jumbo dividend of DKK 26 offers a yield of 14.
ChargePanel publicerade den 23 februari år 2023 bolagets delårsrapport för det fjärde kvartalet 2022...
AcuCort publicerade den 24 februari bolagets delårsrapport för det fjärde kvartalet år 2022 och står...
